The TaperGuard endotracheal tube reduces leakage past the cuff by at least 81 percent compared with the Mallinckrodt Hi-Lo endotracheal tube, potentially reducing the risk of post-surgical complications that may be caused by aspiration of fluids into the lungs, according to the report.
“The TaperGuard endotracheal tubes offer significant advantages for anesthesiologists, surgeons and their patients,” Jim Willett, general manager and vice president of airway and ventilation for Covidien, said in the report. “This FDA 510(k) clearance means more physicians will gain awareness of this innovative product and incorporate its use into their procedures, confirming Covidien’s mission to provide solutions designed to improve patient safety, medical efficacy and healthcare efficiency.”
Read the Covidien release about Mallinckrodt TaperGuard Evac Endotracheal Tubes.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
